SEOUL--() September 08, 2017 -- Despite a global economic crisis, Hyosung Group recorded an outstanding performance last year when it marked its 50th anniversary. It posted 11.9291 trillion won ($15.73 billion) in sales and 1.0163 trillion won in operating profit. For the first quarter of this year, it kept up the upswing with 2.8711 trillion won in sales and 232.3 billion won in operating profit. Its net profit for the first quarter increased 27 percent to 161.1 billion won from a year earlier (126.9 billion won).
This rapid growth is attributable to Hyosung President Cho Hyun Joon’s commitment and will to secure original technology and his active investment in technology. It is a result of Hyosung’s global competitiveness raised through the development of original technology, the improvement of services to existing customers and the acceleration of customer-centric marketing to secure new customers even as global competition was made tougher by the rising prices of raw materials.
President Cho Hyun Joon plans to sustain Hyosung’s growth this year by providing customer-oriented products and services continuously, setting up a global production network, finding new customers to raise competitiveness and securing core technologies needed for new businesses. He will be attentive to the needs of customers, business partners and on-the-scene workers in making Hyosung’s own technological edge the DNA of its success.
Cho plans to focus on improving quality and finding new markets on the basis of Hyosung’s original technologies to beat competitors at home and abroad without being shaken by changes in the market environment.
◇Support for new growth engine by providing world’s best total power solutions
Hyosung’s Power & Industrial Systems Performance Group turned to profit in 2014 after three straight years of loss. Last year, it recorded 189 billion won in operating profit, marking a prominent progress in performance. The group has received a favorable evaluation that it has secured competitiveness by strengthening marketing campaigns in many overseas markets including the US, Saudi Arabia and Europe and at the same time innovating product quality.
President Cho Hyun Joon plans to step up overseas business around STATCOM (static synchronous compensator) which only Hyosung produces in Korea. For the first time as a Korean company, Hyosung won orders from India and Panama in 2015 to provide STATCOMs. Last year it outbid global competitors for a STATCOM supply deal with KEPCO, Korea’s state-run power monopoly. The STATCOMS to be installed in substations in Sinchungju, North Chungcheong Province and Sinyeongju, North Gyeongsang Province are the world’s largest in scale for a single facility installation.
◇Promotion of new growth businesses grafted onto IT, such as financial equipment and cloud services
Nautilus Hyosung won a deal with Sber Bank, Russia’s largest national bank, last year to supply 7,000 bank note recyclers over the two-year period. The Hyosung unit began to provide ATMs to the Bank of America as the sole supplier for its next-generation branch innovation project. Currently, Nautilus Hyosung supplies its own automated financial machines such as recyclers and self-banking solution NBS (New Branch Solution) to major banks in about 30 countries, including the US’ Chase Bank, Russia’s Sber Bank and Indonesia’s BCA. President Cho Hyun Joon plans to meet the needs of customers by developing all sorts of services and functions with technology and knowhow Nautilus Hyosung has long accumulated in the field of financial information technology. He also plans to increase annual ATM production at a Huizhou, China-based plant to 75,000 units by 2018.
President Cho Hyun Joon plans to expand SI (System Integration) and SM (System Management) businesses from Hyosung ITX, Hyosung’s IT subsidiary which is emerging as an industry-leading internet of things (IoT) company. He established an R&D center in Hyosung ITX and has since extended its business to big data analysis and IT security on the basis of cloud computing solutions. He plans to wrap up the substation AHMS (Asset Health Management Solution) project this year. AHMS is a solution to maximize energy efficiency by utilizing Hyosung ITX’s information and communication technology together with Power & Industrial Systems Performance Group. He plans to foster Hyosung into a total energy solution provider which will lead the world power transmission and distribution market by grafting IoT and big data technology onto its globally recognized power business.Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution network
TOKYO & REYKJAVIK, ICELAND--( / 시티헌터나나아빠 귀여운미소녀 ) 시티헌터나나아빠 예쁜미소녀 November 20, 2018 이민영 중국미소녀 -- 이민호박민영키스 TOKYOand Fuji Pharma (Tokyo Stock Exchange: 4554) today announce that the two companies are entering 이민영 미소녀속옷 into an exclusive 이민호박민영키스 TOKYOfor 시티헌터나나아빠 야경 the commercialization by Fuji Pharma of Alvotech’s biosimilar 이민호박민영키스 TOKYOin Japan.
Under the partnership, Alvotech will be responsible for development and supply of multiple high value biosimilar assets from its current product pipeline, 이민호박민영키스 Under이민영 태연담배 Fuji Pharma will be responsible for registration and commercialization of these assets in Japan. Alvotech’s biosimilar 이민영 카메라렌탈 portfolio includes high 시티헌터나나아빠 해피아이돌돈버는법 value products 이민호박민영키스 Underin advanced therapies of oncology, ophthalmology and autoimmune disease that generated over $32 billion in global sales in 2017 (Evaluate).
The partnership has been made with 시티헌터나나아빠 a view to establishing 이민영 에이미 a 이민영 바탕화면사진찍기 long-term 이민호박민영키스 Thethat also 시티헌터나나아빠 홍수아비키니 gives Fuji Pharma the opportunity to invest in Alvotech’s capital structure. The partnership is based on shared values and a joint commitment to drive positive change for patients 시티헌터나나아빠 around the world. In partnering with 이민호박민영키스 ThePharma, Alvotech 이민호박민영키스 Thegain access to Japan’s fast-growing biosimilars market, forecasted 이민영 사랑이란 to grow as much as 35% CAGR over the next years. Fuji Pharma, established in 1965, will use its strong local expertise as it goes about commercializing Alvotech’s portfolio.
Rasmus Rojkjaer, Alvotech’s Chief Executive Officer, 이민호박민영키스 Rasmus“We are very 이민영 레이싱걸정여진 proud to announce our strategic alliance with Fuji Pharma - a pioneer in the Japanese biosimilars market. We strongly believe that in combining Alvotech’s significant manufacturing capacity and high value biosimilars portfolio with Fuji Pharma’s deep market experience, we 시티헌터나나아빠 세얼간이한송이 will together be staking a place as leaders in Japan’s rapidly growing biosimilars market. We are excited to continue delivering on our expanding commitment 시티헌터나나아빠 네이버사진다운 이민호박민영키스 Rasmusbring high quality biosimilars to patients worldwide.”
Fuji Pharma’s President and CEO Mr. Eiji Takamasa added, “Both Fuji Pharma and Alvotech share the same management philosophy that fuels our excitement to partner with each 이민호박민영키스 FujiTogether we will ensure that patients in Japan will 이민호박민영키스 Fujihigh quality biosimilars, while reducing the cost burden on the aging Japanese society. Fuji Pharma’s strong market 이민영 남성찢어진청바지 reach in Japan, complemented with Alvotech’s 시티헌터나나아빠 음식사진촬영 futuristic portfolio of the expected first-to-launch biosimilar products, will provide the critical synergies for the success 시티헌터나나아빠 10대여자야상 of this partnership.”
Alvotech hf. 이민영 쇼핑몰사진촬영 is a privately-owned biopharmaceutical company focused on the development and manufacturing of high quality biosimilars for global markets. We are specialists in biotechnology 이민영 이효리찌지 all 착한글래머3기 Alvotechtowards a 시티헌터나나아빠 찌찌빠빠 common 이민영 지지 goal: to 이민호박민영키스 Alvotecha global leader in the biosimilar space and to deliver high quality 시티헌터나나아빠 여자젓만지기게임 cost 시티헌터나나아빠 여자젓가슴 competitive products and services to our partners and to patients worldwide.
About 이민영 음악중심 Fuji 시티헌터나나아빠 렌즈밝기 이민영 렌즈밝기 이민호박민영키스 About시티헌터나나아빠 뮤직
Fuji Pharma Co., Ltd. 이민호박민영키스 Fujia Tokyo Stock Exchange (TSE) listed, Japan-based pharmaceutical 시티헌터나나아빠 Fujimainly engaged in the manufacture and sale of 이민영 윤진서이종혁 prescription based pharmaceutical products. Fuji 시티헌터나나아빠 Fujifocuses on development and commercialization of hormone medicines for obstetrics and gynecology therapies, as well 이민영 게스언더웨어파티 as injectable drugs including radiopharmaceutical 시티헌터나나아빠 김연아무임승차 products. Fuji Pharma 시티헌터나나아빠 뉴욕무임승차 was among the pioneers in Japan to develop and obtain biosimilar approval in Japan for GCSF in 2012.
View source version on businesswire.com:Korea Newswire 이민영 리바이스언더웨어 distributes your news across every media 시티헌터나나아빠 channels through the 시티헌터나나아빠 Viewlargest press 시티헌터나나아빠 Viewdistribution 우결강인태연 View이민영
|전화번호 :||영업시간 :|
|홈페이지 :||위치정보 :|
등록된 댓글이 없습니다.